The University of Chicago Header Logo

Connection

Sarosh Rana to Biomarkers

Back to Details
This is a "connection" page, showing publications Sarosh Rana has written about Biomarkers.
Sarosh Rana
Connection Strength
4.449
Biomarkers
  1. Clinical utility of angiogenic biomarkers. Am J Obstet Gynecol. 2024 06; 230(6):e124.
    View in: PubMed
    Score: 0.520
  2. Association of antepartum blood pressure levels and angiogenic profile among women with chronic hypertension. Pregnancy Hypertens. 2018 Oct; 14:110-114.
    View in: PubMed
    Score: 0.356
  3. Angiogenic biomarkers in triage and risk for preeclampsia with severe features. Pregnancy Hypertens. 2018 Jul; 13:100-106.
    View in: PubMed
    Score: 0.349
  4. Placental origins of angiogenic dysfunction in mirror syndrome. Hypertens Pregnancy. 2012; 31(2):211-7.
    View in: PubMed
    Score: 0.223
  5. The use of angiogenic biomarkers to differentiate non-HELLP related thrombocytopenia from HELLP syndrome. J Matern Fetal Neonatal Med. 2010 May; 23(5):366-70.
    View in: PubMed
    Score: 0.200
  6. Placental Biomarker Testing for Evaluation of Suspected Preeclampsia. Clin Chem. 2025 May 02; 71(5):548-558.
    View in: PubMed
    Score: 0.141
  7. Neonatal cost savings in hypertensive disorders of pregnancy: Economic evaluation of the sFlt-1/PlGF test with real world implementation of biomarkers. Pregnancy Hypertens. 2025 Mar; 39:101190.
    View in: PubMed
    Score: 0.138
  8. Real-world evidence for the utility of serum soluble fms-like tyrosine kinase 1/placental growth factor test for routine clinical evaluation of hospitalized women with hypertensive disorders of pregnancy. Am J Obstet Gynecol. 2025 Apr; 232(4):385.e1-385.e21.
    View in: PubMed
    Score: 0.134
  9. Plasma soluble fms-like tyrosine kinase 1 to placental growth factor ratio of 11.5 multiples of median predicts preeclampsia with severe features within 2 weeks of testing. Am J Obstet Gynecol. 2024 Sep; 231(3):363.e1-363.e11.
    View in: PubMed
    Score: 0.132
  10. Association of fetal sex with angiogenic factors in normotensive and hypertensive pregnancy states. Pregnancy Hypertens. 2022 Aug; 29:108-115.
    View in: PubMed
    Score: 0.116
  11. Angiogenic Biomarkers for Risk Stratification in Women with Preeclampsia. Clin Chem. 2022 06 01; 68(6):771-781.
    View in: PubMed
    Score: 0.115
  12. Women's perspectives and attitudes towards the utility of angiogenic biomarkers in preeclampsia. Pregnancy Hypertens. 2022 Jun; 28:109-113.
    View in: PubMed
    Score: 0.114
  13. The interval between births and the risk of recurrent preeclampsia among predominantly high risk women in urban tertiary care center. Pregnancy Hypertens. 2021 Aug; 25:7-11.
    View in: PubMed
    Score: 0.107
  14. Use of the angiogenic biomarker profile to risk stratify patients with fetal growth restriction. Am J Obstet Gynecol MFM. 2021 07; 3(4):100394.
    View in: PubMed
    Score: 0.107
  15. Real-World Use of Biomarkers in Management of Hypertension During Pregnancy: Adjunct to Clinical Care. Hypertension. 2021 02; 77(2):472-474.
    View in: PubMed
    Score: 0.105
  16. Real life outpatient biomarker use in management of hypertensive pregnancies in third trimester in a low resource SeTting: ROBUST study. Pregnancy Hypertens. 2021 Mar; 23:97-103.
    View in: PubMed
    Score: 0.104
  17. Imbalances in circulating angiogenic factors in the pathophysiology of preeclampsia and related disorders. Am J Obstet Gynecol. 2022 02; 226(2S):S1019-S1034.
    View in: PubMed
    Score: 0.103
  18. Evaluation of angiogenic factors in the decision to admit women with suspected preeclampsia. Pregnancy Hypertens. 2020 Jul; 21:124-131.
    View in: PubMed
    Score: 0.100
  19. Angiogenic factor abnormalities and risk of peripartum complications and prematurity among urban predominantly obese parturients with chronic hypertension. Pregnancy Hypertens. 2020 Apr; 20:124-130.
    View in: PubMed
    Score: 0.099
  20. Angiogenic Factor Estimation as a Warning Sign of Preeclampsia-Related Peripartum Morbidity Among Hospitalized Patients. Hypertension. 2019 04; 73(4):868-877.
    View in: PubMed
    Score: 0.093
  21. Preeclampsia: Pathophysiology, Challenges, and Perspectives Circ Res. 2019 03 29; 124(7):1094-1112.
    View in: PubMed
    Score: 0.093
  22. Activin A and Late Postpartum Cardiac Dysfunction Among Women With Hypertensive Disorders of Pregnancy. Hypertension. 2018 07; 72(1):188-193.
    View in: PubMed
    Score: 0.087
  23. Angiogenic Proteins: Can These Biomarkers Help to Prevent Maternal Deaths Related to Preeclampsia? Hypertension. 2017 03; 69(3):401-403.
    View in: PubMed
    Score: 0.080
  24. Circulating Antiangiogenic Factors and Myocardial Dysfunction in Hypertensive Disorders of Pregnancy. Hypertension. 2016 06; 67(6):1273-80.
    View in: PubMed
    Score: 0.076
  25. KRYPTOR-automated angiogenic factor assays and risk of preeclampsia-related adverse outcomes. Hypertens Pregnancy. 2016 Aug; 35(3):330-45.
    View in: PubMed
    Score: 0.075
  26. Sequential plasma angiogenic factors levels in women with suspected preeclampsia. Am J Obstet Gynecol. 2016 Jul; 215(1):89.e1-89.e10.
    View in: PubMed
    Score: 0.074
  27. Modeling risk for severe adverse outcomes using angiogenic factor measurements in women with suspected preterm preeclampsia. Prenat Diagn. 2015 Apr; 35(4):386-93.
    View in: PubMed
    Score: 0.069
  28. Angiogenic factors in preeclampsia: potential for diagnosis and treatment. Curr Opin Nephrol Hypertens. 2013 Nov; 22(6):643-50.
    View in: PubMed
    Score: 0.064
  29. Angiogenic factors in diagnosis, management, and research in preeclampsia. Hypertension. 2014 Feb; 63(2):198-202.
    View in: PubMed
    Score: 0.064
  30. Circulating angiogenic factors and risk of adverse maternal and perinatal outcomes in twin pregnancies with suspected preeclampsia. Hypertension. 2012 Aug; 60(2):451-8.
    View in: PubMed
    Score: 0.058
  31. Impact of PlGF immunoassay imprecision on preeclampsia risk assessment with the sFlt-1 to PlGF ratio. Am J Clin Pathol. 2025 Aug 26; 164(2):200-206.
    View in: PubMed
    Score: 0.036
  32. Reference Range Determination for the sFlt-1/PlGF Ratio in a Diverse Cohort of Pregnant Women in the United States. J Appl Lab Med. 2025 Jul 01; 10(4):937-948.
    View in: PubMed
    Score: 0.036
  33. Circulating follistatin-like 3 and its association with postpartum cardiovascular dysfunction and severe maternal morbidity. Pregnancy Hypertens. 2025 Jun; 40:101206.
    View in: PubMed
    Score: 0.035
  34. The additive role of angiogenic markers for women with confirmed preeclampsia. Am J Obstet Gynecol. 2023 05; 228(5):573.e1-573.e11.
    View in: PubMed
    Score: 0.030
  35. Clinical interpretation and implementation of the sFlt-1/PlGF ratio in the prediction, diagnosis and management of preeclampsia. Pregnancy Hypertens. 2022 Mar; 27:42-50.
    View in: PubMed
    Score: 0.028
  36. Long-Term Postpartum Cardiac Function and Its Association With Preeclampsia. J Am Heart Assoc. 2021 02; 10(5):e018526.
    View in: PubMed
    Score: 0.026
  37. Antepartum Aspirin Administration Reduces Activin A and Cardiac Global Longitudinal Strain in Preeclamptic Women. J Am Heart Assoc. 2020 06 16; 9(12):e015997.
    View in: PubMed
    Score: 0.025
  38. Analytical validation of soluble fms-like tyrosine and placental growth factor assays on B·R·A·H·M·S KRYPTOR Compact Plus automated immunoassay platform. Pregnancy Hypertens. 2018 Jan; 11:66-70.
    View in: PubMed
    Score: 0.021
  39. Household air pollution and angiogenic factors in pregnant Nigerian women: A randomized controlled ethanol cookstove intervention. Sci Total Environ. 2017 Dec 01; 599-600:2175-2181.
    View in: PubMed
    Score: 0.020
  40. Angiogenic factor imbalance early in pregnancy predicts adverse outcomes in patients with lupus and antiphospholipid antibodies: results of the PROMISSE study. Am J Obstet Gynecol. 2016 Jan; 214(1):108.e1-108.e14.
    View in: PubMed
    Score: 0.018
  41. The course of angiogenic factors in early- vs. late-onset preeclampsia and HELLP syndrome. J Perinat Med. 2013 Sep 01; 41(5):511-6.
    View in: PubMed
    Score: 0.016
  42. Mid-pregnancy levels of angiogenic markers as indicators of pathways to preterm delivery. J Matern Fetal Neonatal Med. 2012 Jul; 25(7):1135-41.
    View in: PubMed
    Score: 0.014
  43. Role of oxidative stress and antioxidant supplementation in pregnancy disorders. Am J Clin Nutr. 2011 Dec; 94(6 Suppl):1980S-1985S.
    View in: PubMed
    Score: 0.013
  44. Midpregnancy levels of angiogenic markers in relation to maternal characteristics. Am J Obstet Gynecol. 2011 Mar; 204(3):244.e1-12.
    View in: PubMed
    Score: 0.013
  45. Circulating soluble endoglin and placental abruption. Prenat Diagn. 2008 Sep; 28(9):852-8.
    View in: PubMed
    Score: 0.011
  46. Circulating levels of the antiangiogenic marker soluble FMS-like tyrosine kinase 1 are elevated in women with pregestational diabetes and preeclampsia: angiogenic markers in preeclampsia and preexisting diabetes. Diabetes Care. 2007 Feb; 30(2):375-7.
    View in: PubMed
    Score: 0.010
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.